Lifecore Biomedical Q1 revenue up 26% to $31.1M; Adjusted EBITDA turns positive at $3.1M

LIFECORE BIOMEDICAL, INC. DE

2026-Q1 EPS reported -$0.29 revenue$31,109,000

Revenue $31.1M (+26% YoY), driven by HA manufacturing (+$4.8M) and CDMO growth.
Net loss narrowed to $10.0M ($0.29 loss per share) from $16.2M ($0.53) a year ago.
Adjusted EBITDA of $3.1M vs negative $1.8M in prior year; SG&A down $5.9M.
Affirms transition period guidance: revenue $74-76M, Adjusted EBITDA $12-14M.
Signed 4 new programs (2 post-quarter); commercial site transfer with large pharma.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.